• ExpreS2ion Biotech Holding AB set a directed share issue of 11,869,138 new shares to Vator Securities at SEK 1.60.
• A separate set-off issue of 3,627,627 shares to Vator Securities covered guarantee compensation tied to the TO 13 warrant program.
• Combined with TO 13 exercises, gross proceeds total about SEK 19.3 million before costs to fund ES2B-C001 through the primary Phase I readout.
• Total new shares from TO 13, the directed issue, and the compensation issue lift shares outstanding to 39,468,701 from 23,748,983.
• Dilution is about 39.8% on a post-registration basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.